


Amendments to the Claims:

1. (currently amended) The use of A method for inhibiting 11 $\beta$ HSD1, comprising administering to a warm-blooded animal a compound of formula (I):



wherein:

**Ring A** is selected from carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by ~~a group selected from R<sup>9</sup>~~;

**R<sup>1</sup>** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>1</sup> may be optionally substituted on carbon by one or more ~~groups selected from R<sup>3</sup>~~; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by ~~a group selected from R<sup>4</sup>~~;

**n** is 0-5; wherein the values of R<sup>1</sup> may be the same or different;

**X** is a direct bond, -C(O)-, -S(O)<sub>2</sub>-, -C(O)NR<sup>11</sup>-, -C(S)NR<sup>11</sup>-, -C(O)O-, -C(=NR<sup>11</sup>)- or -CH<sub>2</sub>-; wherein **R<sup>11</sup>** is selected from hydrogen, C<sub>1-4</sub>alkyl, carbocyclyl and heterocyclyl;

**Y** is hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more R<sup>2</sup>; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by ~~a group selected from R<sup>5</sup>~~;

**R<sup>2</sup>** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino,

*N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, aminothiocabonylthio, *N*-(C<sub>1-4</sub>alkyl)aminothiocabonylthio, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>aminothiocabonylthio, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more ~~groups selected from R<sup>6</sup>~~; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by ~~a group selected from R<sup>7</sup>~~;

R<sup>3</sup> and R<sup>6</sup> are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>3</sup> and R<sup>6</sup> may be independently optionally substituted on carbon by one or more R<sup>8</sup>; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by ~~a group selected from R<sup>13</sup>~~;

R<sup>4</sup>, R<sup>5</sup>, R<sup>7</sup>, R<sup>9</sup> and R<sup>13</sup> are independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

R<sup>8</sup> is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl,

methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl,

*N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;

**Z** is -S(O)<sub>a</sub>-, -O-, -NR<sup>10</sup>-, -C(O)-, -C(O)NR<sup>10</sup>-, -NR<sup>10</sup>C(O)-, -OC(O)NR<sup>10</sup>- or -SO<sub>2</sub>NR<sup>10</sup>-;

wherein **a** is 0 to 2; wherein **R**<sup>10</sup> is selected from hydrogen and C<sub>1-4</sub>alkyl;

**R**<sup>12</sup> is hydroxy, methyl, ethyl or propyl;

**m** is 0 or 1;

**q** is 0 or 1;

or a pharmaceutically acceptable salt thereof;

~~in the manufacture of a medicament for use in the inhibition of 11 $\beta$ HSD1.~~

2. (currently amended) The use method of a compound of formula ~~(I)~~ as claimed in claim 1, wherein Ring A is phenyl, 1,3-benzodioxolyl, thienyl, cyclopentyl, pyridyl, furyl, thiazolyl, 1,3-benzothiazolyl, benzofuryl or benzothienyl; or a pharmaceutically acceptable salt thereof.

3. (currently amended) The use method of a compound of formula ~~(I)~~ as claimed in any one of claims 1-2 claim 1, wherein

**R**<sup>1</sup> is a substituent on carbon and is selected from halo, cyano, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy,

*N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein **a** is 0 to 2, carbocyclyl and

carbocyclylC<sub>0-4</sub>alkylene-Z-; wherein **R**<sup>1</sup> may be optionally substituted on carbon by one or more ~~groups selected from~~ **R**<sup>3</sup>; wherein **R**<sup>3</sup> is selected from halo, hydroxy, C<sub>1-4</sub>alkoxy, heterocyclyl and carbocyclylC<sub>0-4</sub>alkylene-Z-; and

**Z** is -S(O)<sub>a</sub>- or -O-; wherein **a** is 0 to 2;

or a pharmaceutically acceptable salt thereof.

4. (currently amended) The use method of a compound of formula ~~(I)~~ as claimed in any one of claims 1-3 claim 1, wherein **n** is 0-3; and wherein the values of **R**<sup>1</sup> may be the same or different; or a pharmaceutically acceptable salt thereof.

5. (currently amended) The use method of a compound of formula ~~(I)~~ as claimed in any one of claims 1-4 claim 1, wherein **X** is -C(O)-; or a pharmaceutically acceptable salt thereof.

6. (currently amended) The use method of a compound of formula (I) as claimed in any one of claims 1-5 claim 1, wherein

Y is hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more R<sup>2</sup>; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from R<sup>5</sup>; wherein R<sup>2</sup> is a substituent on carbon and is selected from halo, nitro, cyano, amino, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>aminothiocabonylthio, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more groups selected from R<sup>6</sup>;

R<sup>6</sup> is selected from halo, nitro, cyano, trifluoromethyl, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>1-4</sub>alkoxy, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonylamino, carbocyclyl, heterocyclyl and carbocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>6</sup> may be optionally substituted on carbon by one or more R<sup>8</sup>;

R<sup>5</sup> is selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl and C<sub>1-4</sub>alkoxycarbonyl;

Z is -S(O)<sub>a</sub>-, -O-, -NR<sup>10</sup>-, -C(O)- or -OC(O)NR<sup>10</sup>-; wherein a is 0 to 2; wherein R<sup>10</sup> is selected from hydrogen; and

R<sup>8</sup> is selected from halo;

or a pharmaceutically acceptable salt thereof.

7. (currently amended) The use method of a compound of formula (I) as claimed in any one of claims 1-6 claim 1, wherein R<sup>12</sup> is 4-methyl, 4-ethyl, 4-propyl or 3-methyl; or a pharmaceutically acceptable salt thereof.

8. (currently amended) The use method of a compound of formula (I) as claimed in any one of claims 1-7 claim 1, wherein q is 0; or a pharmaceutically acceptable salt thereof.

9. (currently amended) The use method of a compound of formula (I) as depicted in claim 1, wherein:

Ring A is phenyl, 1,3-benzodioxolyl, thienyl, cyclopentyl, pyridyl, furyl, thiazolyl, 1,3-benzothiazolyl, benzofuryl or benzothienyl;

$R^1$  is a substituent on carbon and is selected from halo, cyano,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>amino,  $C_{1-4}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2, carbocyclyl and carbocyclylC<sub>0-4</sub>alkylene-Z-; wherein  $R^1$  may be optionally substituted on carbon by one or more ~~groups selected from~~  $R^3$ ; wherein

$R^3$  is selected from halo, hydroxy,  $C_{1-4}$ alkoxy, heterocyclyl and carbocyclylC<sub>0-4</sub>alkylene-Z-; and Z is -S(O)<sub>a</sub>- or -O-; wherein a is 0 to 2;

X is a direct bond, -C(O)-, -S(O)<sub>2</sub>-, -C(O)NR<sup>11</sup>-, -C(S)NR<sup>11</sup>-, -C(O)O-, -C(=NR<sup>11</sup>)- or -CH<sub>2</sub>-; wherein  $R^{11}$  is selected from hydrogen,  $C_{1-4}$ alkyl, carbocyclyl and heterocyclyl;

Y is hydrogen,  $C_{1-6}$ alkyl,  $C_{2-6}$ alkenyl,  $C_{2-6}$ alkynyl, carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more  $R^2$ ; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a ~~group selected from~~  $R^5$ ; wherein  $R^2$  is a substituent on carbon and is selected from halo, nitro, cyano, amino, trifluoromethyl, trifluoromethoxy,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,  $C_{1-4}$ alkanoyl,  $N$ -( $C_{1-4}$ alkyl)amino,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>amino,  $C_{1-4}$ alkanoylamino,  $C_{1-4}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-4}$ alkoxycarbonylamino,  $C_{1-4}$ alkoxycarbonyl- $N$ -( $C_{1-4}$ alkyl)amino,  $N$ -( $C_{1-4}$ alkyl)sulphamoyl,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>sulphamoyl,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>aminothiocabonylthio, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein  $R^2$  may be optionally substituted on carbon by one or more ~~groups selected from~~  $R^6$ ;

$R^6$  is selected from halo, nitro, cyano, trifluoromethyl,  $C_{1-4}$ alkyl,  $C_{2-4}$ alkenyl,  $C_{1-4}$ alkoxy,  $N,N$ -( $C_{1-4}$ alkyl)<sub>2</sub>amino,  $C_{1-4}$ alkylS(O)<sub>a</sub> wherein a is 0 to 2,  $C_{1-4}$ alkoxycarbonylamino, carbocyclyl, heterocyclyl and carbocyclylC<sub>0-4</sub>alkylene-Z-; wherein  $R^6$  may be optionally substituted on carbon by one or more  $R^8$ ;

$R^5$  is selected from  $C_{1-4}$ alkyl,  $C_{1-4}$ alkanoyl and  $C_{1-4}$ alkoxycarbonyl;

Z is -S(O)<sub>a</sub>-, -O-, -NR<sup>10</sup>-, -C(O)- or -OC(O)NR<sup>10</sup>-; wherein a is 0 to 2; wherein  $R^{10}$  is selected from hydrogen; and

$R^8$  is selected from halo;

$R^{12}$  is hydroxy, methyl, ethyl or propyl;

m is 0 or 1; and

q is 0 or 1;

or a pharmaceutically acceptable salt thereof[;]

~~in the manufacture of a medicament for use in the inhibition of 11 $\beta$ HSD1.~~

10. (currently amended) A compound of formula (I) as claimed in any one of claims 1-9 selected from:

1-(3-fluoro-4-methoxybenzoyl)-4-(4-fluorobenzoyl)piperidine;

1-(quinoline-3-ylcarbonyl)-4-(4-fluorobenzoyl)piperidine;

1-(quinoline-2-ylcarbonyl)-4-(4-fluorobenzoyl)piperidine;

1-(5-trifluoromethylfur-2-yl)-4-(4-fluorobenzoyl)piperidine;

1-(3-trifluoromethoxybenzoyl)-4-(4-fluorobenzoyl)piperidine;

1-(tetrahydrofur-2-ylcarbonyl)-4-(4-chlorobenzoyl)piperidine;

1-(5-trifluoromethylfur-2-yl)-4-(4-chlorobenzoyl)piperidine;

1-(pyrid-2-ylcarbonyl)-4-(4-chlorobenzoyl)piperidine;


1-(thiazol-4-ylcarbonyl)-4-(4-chlorobenzoyl)piperidine;

1-(3,3,3-trifluoropropionyl)-4-(4-fluorobenzoyl)piperidine;

1-(4-fluorobenzoyl)-4-(3-mesylbenzoyl)piperidine;

or a pharmaceutically acceptable salt thereof.

11. (currently amended) A compound of formula (Ig):



wherein:

$R^1$  is a substituent on carbon and is selected from halo, cyano,  $C_{1-4}$ alkyl,  $C_{1-4}$ alkoxy,

$C_{1-4}alkylS(O)_2$ ,  $N$ -( $C_{1-4}alkyl$ )sulphamoyl or  $N,N$ -( $C_{1-4}alkyl$ )<sub>2</sub>sulphamoyl; wherein  $R^1$  may

be optionally substituted on carbon by one or more ~~groups selected from  $R^3$ ;~~

**n** is 0-3; wherein the values of **R**<sup>1</sup> may be the same or different;

**Y** is phenyl, pyrimidine, furan, thiophene or thiazole; wherein **Y** may be optionally substituted on carbon by one or more **R**<sup>2</sup>;

**R**<sup>2</sup> is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, aminothiocabonylthio, *N*-(C<sub>1-4</sub>alkyl)aminothiocabonylthio or *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>aminothiocabonylthio; wherein **R**<sup>2</sup> may be optionally substituted on carbon by one or more ~~groups selected from~~ **R**<sup>6</sup>;

**R**<sup>3</sup> and **R**<sup>6</sup> are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl or C<sub>1-4</sub>alkylsulphonylamino; wherein **R**<sup>3</sup> and **R**<sup>6</sup> may be independently optionally substituted on carbon by one or more **R**<sup>8</sup>;

**R**<sup>8</sup> is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphanyl, ethylsulphanyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;

**Z** is  $-S(O)_a-$ ,  $-O-$ ,  $-NR^{10}-$ ,  $-C(O)-$ ,  $-C(O)NR^{10}-$ ,  $-NR^{10}C(O)-$ ,  $-OC(O)NR^{10}-$  or  $-SO_2NR^{10}-$ ;

wherein **a** is 0 to 2; wherein  $R^{10}$  is selected from hydrogen and  $C_{1-4}$ alkyl;

$R^{12}$  is hydroxy, methyl, ethyl or propyl;

**m** is 0 or 1;

or a pharmaceutically acceptable salt thereof;

with the proviso that said compound is not 1,4-dibenzoylpiperidine;

4-hydroxy-1,4-dibenzoylpiperidine; 1-(3,4,5-trimethoxybenzoyl)-1-benzoylpiperidine;

1,4-di-(4-methylbenzoyl)piperidine; 1-(4-chlorobenzoyl)-4-benzoylpiperidine;

1-(3-nitrobenzoyl)-4-benzoylpiperidine;

1-(2-methoxy-4,6-difluoromethylbenzoyl)-4-(4-chlorobenzoyl)piperidine;

1-(2,6-difluorobenzoyl)-4-benzoylpiperidine;

1-(3-trifluoromethylbenzoyl)-4-(benzoyl)piperidine;

1-(4-aminobenzoyl)-4-(4-fluorobenzoyl)piperidine;

1-(2-chloro-4-nitrobenzoyl)-4-benzoylpiperidine;

1-(4-methoxybenzoyl)-4-benzoylpiperidine; 1-(4-*t*-butylbenzoyl)-4-benzoylpiperidine;

1-(2,4-dihydroxybenzoyl)-4-(4-fluorobenzoyl)piperidine;

1-(4-nitrobenzoyl)-4-(4-fluorobenzoyl)piperidine;


1-(pyrid-3-ylcarbonyl)-4-(4-fluorobenzoyl)piperidine;

1-(thien-2-ylcarbonyl)-4-benzoylpiperidine;

1-(thien-2-ylcarbonyl)-4-(4-methylbenzoyl)piperidine; or

1-(fur-2-ylcarbonyl)-4-benzoylpiperidine.

12. (currently amended) The use of A method for inhibiting 11 $\beta$ HSD1, comprising administering a compound of formula (Ih):



wherein:



- Ring A** is selected from carbocyclyl or heterocyclyl; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a ~~group selected from R<sup>9</sup>~~;
- R<sup>1</sup>** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>1</sup> may be optionally substituted on carbon by one or more ~~groups selected from R<sup>3</sup>~~; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a ~~group selected from R<sup>4</sup>~~;
- n** is 0-5; wherein the values of R<sup>1</sup> may be the same or different;
- Y** is hydrogen, C<sub>1-6</sub>alkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, carbocyclyl or heterocyclyl; wherein Y may be optionally substituted on carbon by one or more R<sup>2</sup>; wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a ~~group selected from R<sup>5</sup>~~;
- R<sup>2</sup>** is a substituent on carbon and is selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, aminothiocarbonylthio, *N*-(C<sub>1-4</sub>alkyl)aminothiocarbonylthio, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>aminothiocarbonylthio, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein R<sup>2</sup> may be optionally substituted on carbon by one or more ~~groups selected from R<sup>6</sup>~~; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a ~~group selected from R<sup>7</sup>~~;

**R<sup>3</sup>** and **R<sup>6</sup>** are independently selected from halo, nitro, cyano, hydroxy, amino, carboxy, carbamoyl, mercapto, sulphamoyl, trifluoromethyl, trifluoromethoxy, C<sub>1-4</sub>alkyl, C<sub>2-4</sub>alkenyl, C<sub>2-4</sub>alkynyl, C<sub>1-4</sub>alkoxy, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkanoyloxy, *N*-(C<sub>1-4</sub>alkyl)amino, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>amino, C<sub>1-4</sub>alkanoylamino, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, C<sub>1-4</sub>alkylS(O)<sub>a</sub> wherein a is 0 to 2, C<sub>1-4</sub>alkoxycarbonyl, C<sub>1-4</sub>alkoxycarbonylamino, C<sub>1-4</sub>alkoxycarbonyl-*N*-(C<sub>1-4</sub>alkyl)amino, *N*-(C<sub>1-4</sub>alkyl)sulphamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>sulphamoyl, C<sub>1-4</sub>alkylsulphonylamino, carbocyclyl, heterocyclyl, carbocyclylC<sub>0-4</sub>alkylene-Z- and heterocyclylC<sub>0-4</sub>alkylene-Z-; wherein **R<sup>3</sup>** and **R<sup>6</sup>** may be independently optionally substituted on carbon by one or more **R<sup>8</sup>**; and wherein if said heterocyclyl contains an -NH- moiety that nitrogen may be optionally substituted by a group selected from **R<sup>13</sup>**;

**R<sup>4</sup>**, **R<sup>5</sup>**, **R<sup>7</sup>**, **R<sup>9</sup>** and **R<sup>13</sup>** are independently selected from C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkanoyl, C<sub>1-4</sub>alkylsulphonyl, C<sub>1-4</sub>alkoxycarbonyl, carbamoyl, *N*-(C<sub>1-4</sub>alkyl)carbamoyl, *N,N*-(C<sub>1-4</sub>alkyl)<sub>2</sub>carbamoyl, benzyl, benzyloxycarbonyl, benzoyl and phenylsulphonyl;

**R<sup>8</sup>** is selected from halo, nitro, cyano, hydroxy, trifluoromethoxy, trifluoromethyl, amino, carboxy, carbamoyl, mercapto, sulphamoyl, methyl, ethyl, methoxy, ethoxy, acetyl, acetoxymethyl, methylamino, ethylamino, dimethylamino, diethylamino, *N*-methyl-*N*-ethylamino, acetylamino, *N*-methylcarbamoyl, *N*-ethylcarbamoyl, *N,N*-dimethylcarbamoyl, *N,N*-diethylcarbamoyl, *N*-methyl-*N*-ethylcarbamoyl, methylthio, ethylthio, methylsulphinyl, ethylsulphinyl, mesyl, ethylsulphonyl, methoxycarbonyl, ethoxycarbonyl, *N*-methylsulphamoyl, *N*-ethylsulphamoyl, *N,N*-dimethylsulphamoyl, *N,N*-diethylsulphamoyl or *N*-methyl-*N*-ethylsulphamoyl;

**Z** is -S(O)<sub>a</sub>-, -O-, -NR<sup>10</sup>-, -C(O)-, -C(O)NR<sup>10</sup>-, -NR<sup>10</sup>C(O)-, -OC(O)NR<sup>10</sup>- or -SO<sub>2</sub>NR<sup>10</sup>-; wherein a is 0 to 2; wherein **R<sup>10</sup>** is selected from hydrogen and C<sub>1-4</sub>alkyl;

**R<sup>12</sup>** is hydroxy, methyl, ethyl or propyl;

**m** is 0 or 1;

or a pharmaceutically acceptable salt thereof;

in the manufacture of a medicament for use in the inhibition of 11 $\beta$ HSD1.

13. (currently amended) A pharmaceutical composition ~~which comprises~~ comprising a compound of claim 10 or 11 formula (I) or (Ig), or a pharmaceutically acceptable salt thereof, as ~~claimed in claims 10 or 11~~, in association with a pharmaceutically acceptable diluent or carrier.

14. (cancelled)

15. (cancelled)

16. (currently amended) ~~The use of~~ A method for inhibiting 11 $\beta$ HSD1 in a warm-blooded animal, comprising administering a compound of ~~the formula (I) or (Ig), or a pharmaceutically acceptable salt thereof, as claimed in claims~~ claim 10 or 11, or a pharmaceutically acceptable salt thereof to a warm-blooded animal ~~in the manufacture of a medicament for use in the production of an 11 $\beta$ HSD1 inhibitory effect in a warm-blooded animal, such as man.~~

17. (currently amended) ~~The use as claimed in any one~~ method of ~~claims 1-9, 12 and 16~~ claim 1 or 16 wherein inhibition of production of, or producing an, 11 $\beta$ HSD1 inhibitory effect ~~refers to~~ is associated with the treatment of metabolic syndrome.

18. (currently amended) ~~The use as claimed in any one~~ method of ~~claims 1-9, 12 and 16~~ claim 1 or 16 wherein inhibition of production of, or producing an, 11 $\beta$ HSD1 inhibitory effect ~~refers to~~ is associated with the treatment of diabetes, obesity, hyperlipidaemia, hyperglycaemia, hyperinsulinemia or hypertension, ~~particularly diabetes and obesity.~~

19. (currently amended) ~~The use as claimed in any one~~ method of ~~claims 1-9, 12 and 16~~ claim 1 or 16 wherein inhibition of production of, or producing an, 11 $\beta$ HSD1 inhibitory effect ~~refers to~~ is associated with the treatment of glaucoma, osteoporosis, tuberculosis, dementia, cognitive disorders or depression.

20. (cancelled)

21. (new) The method of claim 18, wherein inhibition of 11 $\beta$ HSD1 is associated with the treatment of diabetes or obesity.